공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

암 치료용 유전체학 시장 : 성장, 동향, 예측(2020-2025년)

Genomics in Cancer Care Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2021년 03월 상품 코드 927883
페이지 정보 영문
US $ 4,250 ₩ 4,788,000 PDF (Single User License)
US $ 4,750 ₩ 5,352,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 6,760,000 PDF (Site License)
US $ 7,500 ₩ 8,451,000 PDF (Corporate License)

암 치료용 유전체학 시장 : 성장, 동향, 예측(2020-2025년) Genomics in Cancer Care Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
발행일 : 2021년 03월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 암 치료용 유전체학 시장은 2020-2025년간 17.5%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예측되고 있습니다. 높은 암 유병률, 암 치료에 대한 활발한 기술 개발이 시장 성장을 촉진하는 요인이 되고 있습니다.

세계의 암 치료용 유전체학(Genomics) 시장을 조사했으며, 시장 개요, 유형·기술·지역별 시장 동향, 시장 규모 추이 및 예측, 시장 성장 촉진요인 및 저해요인, 시장 기회 분석, 경쟁 상황, 주요 기업 프로파일 등의 종합적인 정보를 제공합니다.


제1장 서론

제2장 조사 방법

제3장 개요

제4장 시장 역학

  • 시장 개요
  • 성장 촉진요인
    • 증가하는 암의 부담
    • 제품 개발에서 기업의 이니셔티브
  • 성장 억제요인
    • 높은 비용
  • Five Forces 분석

제5장 시장 세분화

  • 제품 유형별
    • 기기
    • 소모품
    • 서비스
  • 기술 별
    • PCR
    • 마이크로어레이
    • 게놈 시퀀싱
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동 및 아프리카
    • 남미

제6장 경쟁 상황

  • 기업 개요
    • Agilent Technologies
    • Cancer Genetics Inc.
    • GE Healthcare
    • Merck KGaA
    • Illumina Inc.
    • Intrexon Bioinformatics Germany GmbH
    • Pacific Biosciences, Inc.
    • Quest Diagnostics
    • Roche Diagnostics
    • ThermoFisher Scientific Inc.

제7장 시장 기회 및 향후 동향

LSH 20.06.04

The Genomics in Cancer Care market is expected to register a CAGR of 12.5% over the forecast period.

The Genomics field is gaining popularity during the current COVID-19 pandemic, as a routine clinical diagnostic test, which is expected to show a positive impact on the studied market. For instance, in June 2020, Illumina received Emergency Use Authorization (EUA) from the FDA for its COVIDSeq test that is used to sequence the full genome of the novel SARS-CoV-2 virus. This test along with the high-throughput NovaSeq 6000 hardware of Illumina is capable of processing more than 3,000 samples and offers results within 24 hours. Similarly, in August 2020, Helix OpCo LLC received EUA for its Helix COVID-19 NGS Test for the detection of SARS-CoV-2 infection. However, as most of the elective surgeries and treatments were deferred to minimize the transmission of coronavirus and to reserve the healthcare infrastructure for COVID-19 infected patients, the genomics in cancer care has also been affected significantly, as cancer treatments were also postponed. Thus, the COVID-19 pandemic is expected to have a positive impact on COVID-19 based genomics, however, a slightly declining trend was observed with respect to cancer care.

The high prevalence of cancer and biotechnological advancements related to cancer care is expected to be the major factors to propel the market growth. According to the Globocan 2020, an estimated 19,292,789 new cancer cases were diagnosed worldwide, with nearly 9,958,133 deaths due to cancers, globally. Additionally, as per the International Agency for Research on Cancer (IARC), the incidence of cancers cases is expected to grow to 27.5 million new cases and 16.3 million deaths worldwide by 2040. The increasing incidence of cancer cases is expected to drive the need for advanced diagnostics and treatment options for cancers, which in turnis expected to boost the market. Also, the launch of new products and effective strategic collaborations among key players is anticipated to drive the studied market. For instance, in Sep 2020, Thermo Fisher Scientific's Ion Torrent Genexus System and Oncamine Precision Assay was selected by the LC-SCRUM-Asia, a leading cancer genomic screening program, for the advancement of precision medicine in Asia. Thus, in view of the aforementioned factors, the genomic in cancer care market is predicted to register significant growth over the forecast period globally.

Key Market Trends

Genome Sequencing Segment is Expected to Hold a Major Market Share in the Genomics in Cancer Care Market

Emerging technology related to genome sequencing is expected to fuel market growth. Next-Generation sequencing is a novel method having wide application in oncology. The sequencing of DNA and RNA helps in detecting and analyzing the modifiers, mutation analysis, and pharmacogenetics of biopsy.

In the advent of the COVID-19 pandemic, in May 2020, Genomics England partnered with the GenOMICC consortium, which was led by the University of Edinburgh. This partnership was aimed at identifying and analyzing the whole genome sequences of nearly 35,000 COVID-19 infected patients with symptoms ranging from mild to severe. The Genomics England, UK Research and Innovation, the Department of Health and Social Care, and the National Institute for Health Research offered a fund of around GBP 28 million for this project in which Illumina was involved in sequencing all 35,000 genomes. Hence, the genome sequencing segment is expected to significantly grow during the COVID-19 pandemic.

Additionally, as per the research article published in Trends in Cancer, 2019, DNA sequencing and other -omics have been harnessed to study the genetic aberrations of human cancers to obtain information that aids in increasing precision in assigning drugs to patients. For instance, the development of targeted treatments which include small molecule therapeutics targeting specific gene mutations, such as imatinib for c-KIT gene mutation in Chronic Myeloid Leukemia and Gastrointestinal Stromal Tumors. Also, in Aug 2020, AncestryHealth based on Next Generation Sequencing was launched by Ancestry, with an intention to help customers gain awareness into their health and risk factors, as it acts as a vital tool to screen genes associated with breast cancer, heart disease, colon cancer, and blood disorders. Hence, the growing investment in the research and development activities of genome sequencing, along with the novel product launches is expected to aid in the healthy growth of the studied segment over the forecast period.

Also, in October 2019, GENOMIKA, the main genetic testing laboratory in Brazil, reached an agreement with Veritas Intercontinental to incorporate the whole genome and exome sequencing in its portfolio, along with all the services associated with these tests in the field of preventive medicine and clinical genetics.

Furthermore, its advantages over other techniques are known to boost the growth of the studied segment. For instance, in August 2020, the FDA approved the first liquid biopsy companion diagnostic that leverages Next-generation sequencing (NGS) technology to guide cancer treatment. The Guardant360 CDx assay promotes less invasive testing and the simultaneous mapping of several biomarkers of genomic alterations in the tumor.

North America is Expected to Hold a Significant Share in the Market Over the Forecast Period

North America is expected to hold a major market share in the global genomics in cancer care market due to higher incidence rates of cancer disease and the initiatives taken by the government and other organizations related to genomics cancer. According to the Globocan 2020 report, an estimated 2,281,658 new cancer cases were diagnosed in the United States in 2020, with nearly 612,390 deaths. In 2020, The most common cancers were breast (253,465), lung (227,875), prostate (209,512), and colon (101,809) in the United States.

Also, various government bodies, like NHGRI (National Human Genome Research Institute, United States), have been supporting research related to human genome sequencing, while funding research related to the genome's structure, function, and role in health and disease. Moreover, these organizations support studies on the ethical, legal, and social implications of genome research.

Furthermore, in September 2019, Ontario Institute for Cancer Research (OICR), Thermo Fisher Scientific, and Genome Canada collaborated to develop next-generation sequencing assays and analysis software to specifically target pancreatic, prostate, and breast cancer. In April 2020, Genome Canada launched the Canadian COVID Genomics Network (CanCOGeN), a newly formed initiative backed by funding of USD 40 million and led by Genome Canada, in partnership with the six regional Genome Centres, national and provincial public health labs, genome sequencing centers through, hospitals, universities and the private sector, in which the CanCOGeN had planned to scale up genomics-based COVID-19 research in Canada.

Thus, owing to the rising burden of cancers in the region, along with increasing research activities pertaining to genomics, the studied market is expected to witness significant growth in the North American region.

Competitive Landscape

The Genomics in Cancer Care Market is moderately competitive. Some of the companies which are currently dominating the market are Illumina Inc., ThermoFisher Scientific Inc., Agilent Technologies, Cancer Genetics Inc., GE Healthcare (GE Company), Intrexon Bioinformatics Germany GmbH, Quest Diagnostics, Merck KGaA, and Pacific Biosciences, Inc. among others. Companies are adopting growth strategies such as collaborations, mergers, and acquisitions to expand the product portfolio and secure the position among global competitors. For instance, in Jan 2021, Personal Genome Diagnostics Inc entered into a strategic collaboration with QIAGEN to provide its Comprehensive Pan-Cancer Tumor Profiling tests and clinical decision support to molecular labs.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Cancer
    • 4.2.2 Initiatives taken by Companies in Product Development
    • 4.2.3 Speed, Accuracy and Potential Replacement for Traditional Technologies to Spur Market Growth
  • 4.3 Market Restraints
    • 4.3.1 Interpretation of Complex Data and Lack of Skilled Professionals
    • 4.3.2 High Cost of Instruments and Procedures
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Product Type
    • 5.1.1 Instruments
    • 5.1.2 Consumables
    • 5.1.3 Services
  • 5.2 By Technology
    • 5.2.1 PCR
    • 5.2.2 MicroArrays
    • 5.2.3 Genome Sequencing
    • 5.2.4 Others
  • 5.3 Geography
    • 5.3.1 North America
      • United States
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Agilent Technologies, Inc.
    • 6.1.2 Cancer Genetic,s Inc.
    • 6.1.3 GE Healthcare (GE Company)
    • 6.1.4 Merck KGaA
    • 6.1.5 Illumina Inc.
    • 6.1.6 Intrexon Bioinformatics Germany GmbH
    • 6.1.7 Pacific Biosciences of California, Inc.
    • 6.1.8 Quest Diagnostics
    • 6.1.9 F. Hoffmann-La Roche AG
    • 6.1.10 ThermoFisher Scientific Inc.
    • 6.1.11 Bio-Rad Laboratories, Inc.
    • 6.1.12 Qiagen NV
    • 6.1.13 Perkin Elmer
    • 6.1.14 Myriad Genetics, Inc.
    • 6.1.15 Luminex Corporation


Back to Top
전화 문의